OBJECTIVES: Public and private US Payers use CQM to assess the quality of diabetes care and to incentivize improvement in care and associated outcomes. Examples of payers using CQMs include the Medicare Shared Savings Program (MSSP) and HealthPartners (HP).  This post hoc analysis assessed CQM attainment with CANA and SITA in overweight/obese patients with T2DM.    METHODS:  This analysis used pooled data from 2 previously published comparative randomized controlled clinical trials that evaluated CANA and SITA treatment in patients with inadequate glycemic control on current therapy.  CQM attainment was defined as achievement of combined glycated hemoglobin (HbA1c), blood pressure, and low density lipoprotein cholesterol (LDL-C) thresholds. CQM attainment was assessed at baseline and 52 weeks, using last observation carried forward.  Differences between CANA and SITA treatment groups were evaluated using 95% confidence intervals (CI) and odds ratios (OR) based on logistic regression. RESULTS:  Baseline characteristics of 645 CANA and 649 SITA treated patients with body mass index > 25 kg/mand data for CQM assessment were similar.  Baseline CQM attainment was similar between groups.  At 52 weeks, CANA vs SITA demonstrated a greater likelihood of attaining CQMs.  For the HP CQM HbA1c<7%;BP<130/80mmHg;LDL-C<100mg/dL, CANA demonstrated  4.9% (95% CI 1.2;8.5 and OR 1.94, 95% CI 1.30;2.91 ) better attainment. For the MSSP CQM HbA1c<8%;BP<140/90mmHg;LDL-C<100mg/dL CANA demonstrated  6.6% (95% CI 1.4;11.9 and OR 1.58, 95% CI 1.19;2.08) better attainment.  Hypoglycemia rates for each group were similar.  CANA was associated with higher rates of genital mycotic infections and adverse events related to osmotic diuresis, but with few study discontinuations.   CONCLUSIONS: Compared to SITA 100 mg, CANA 300 mg treatment was associated with better CQM attainment in obese/overweight patients with T2DM.  This information may inform payers on the comparative effectiveness of antihyperglycemic agents on attainment of diabetes CQMs which include glycemic, blood pressure, and lipid endpoints.